Guided Therapeutics (GTHP) Long-Term Deferred Tax (2016 - 2024)
Guided Therapeutics' (GTHP) quarterly Long-Term Deferred Tax came in at $17.6 million in Q4 2024, down 16.48% quarter-over-quarter from $21.0 million in Q4 2019.
Guided Therapeutics (GTHP) Long-Term Deferred Tax (2016 - 2024) Analysis & Trends
Guided Therapeutics has disclosed Long-Term Deferred Tax across 5 years of filings, most recently posting $17.6 million for Q4 2024.
- Long-Term Deferred Tax for Q4 2024 came in at $17.6 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2024 was $17.6 million (changed N/A YoY), and the FY2024 annual result was $17.6 million, changed N/A from the prior year.
- Long-Term Deferred Tax came in at $17.6 million for Q4 2024 at Guided Therapeutics, down from $21.0 million in the prior quarter.
- In the past five years, Long-Term Deferred Tax ranged from a high of $17.6 million in Q4 2024 to a low of $17.6 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn |
| 10 | Guided Therapeutics | - | - | 458,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 17.57 Mn |
| Dec 31, 2019 | 21.03 Mn |
| Dec 31, 2018 | 21.47 Mn |
| Dec 31, 2017 | 23.46 Mn |
| Dec 31, 2016 | 29.45 Mn |